Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
| Member | Definition | Class |
|---|
| 1,2-dimethylhydrazine | A member of the class of hydrazines that is hydrazine in which one of the hydrogens attached to each nitrogen is replaced by a methyl group. A powerful DNA alkylating agent and carcinogen, it is used to induce colon cancer in laboratory rats and mice. | 1,2-dimethylhydrazine |
| 4-hydroxycyclophosphamide | A phosphorodiamide that consists of 2-amino-1,3,2-oxazaphosphinan-4-ol 2-oxide having two 2-chloroethyl groups attached to the exocyclic nitrogen. | 4-hydroxycyclophosphamide |
| 5-(3-methyl-1-triazeno)imidazole-4-carboxamide | A monocarboxylic acid amide that is dacarbazine in which one of the methyl groups is replaced by a hydrogen. It is the active metabolite of dacarbazine, and is also produced by spontaneous hydrolysis of temozolomide in the body. | MTIC |
| acrylamide | A member of the class of acrylamides that results from the formal condensation of acrylic acid with ammonia. | acrylamide |
| aziridine | | aziridine |
| bis(chloromethyl) ether | An ether that is dimethyl ether in which one of the hydrogens attached to each of the methyl group has replaced by a chlorine. | bis(chloromethyl) ether |
| bromoethane | A bromoalkane that is ethane carrying a bromo substituent. It is an alkylating agent used as a chemical intermediate in various organic syntheses. | bromoethane |
| bromopyruvate | A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is replaced by bromine. Synthetic brominated derivative and structural analog of pyruvic acid. Highly reactive alkylating agent. Anti-cancer drug | 3-bromo-2-oxopropanoic acid; 3-bromopyruvic acid |
| busulfan | A methanesulfonate ester that is butane-1,4-diol in which the hydrogens of the hydroxy groups are replaced by methanesulfonyl groups. An alkylating antineoplastic agent, it is used for the treatment of chronic myeloid leukemia (although it has been largely replaced by newer drugs). It is also used as an insect sterilant. | busulfan |
| carmustine | A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group. | carmustine |
| chlorambucil | A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia. | chlorambucil |
| chloroacetic acid | A chlorocarboxylic acid that is acetic acid carrying a 2-chloro substituent. | chloroacetic acid |
| colibactin | A member of the class of 1,3-thiazoles that comprises of two units of 2-[(2-{6-[(2S)-2-methyl-3,4-dihydro-2H-pyrrol-5-yl]-5-oxo-4-azaspiro[2.4]hept-6-en-7-yl}acetamido)methyl]-1,3-thiazole-4-carboxylic acid linked together via the formal condensation of the carboxy groups. It is a secondary metabolite produced by certain strains of bacteria found in the human gut such as Escherichia coli. It has the ability to bind covalently to DNA and is strongly associated with colorectal cancer. | colibactin |
| cyclophosphamide | The monohydrate of cyclophosphamide. | cyclophosphamide hydrate |
| dacarbazine | A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma. | dacarbazine |
| dehydroalanine | A 2,3-dehydroamino acid that is alanine which has been dehydrogenated to introduce a double bond between positions 2 and 3. | 2-aminoacrylic acid; 2-ammonioprop-2-enoate |
| diaziquone | A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups. | diaziquone |
| diazomethane | The simplest diazo compound, in which a diazo group is attached to a methylene group. | diazomethane |
| diethyl sulfate | The diethyl ester of sulfuric acid. | diethyl sulfate |
| dimethyl sulfate | The dimethyl ester of sulfuric acid. | dimethyl sulfate |
| dimethyl sulfoxide | A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents. | dimethyl sulfoxide |
| dimethylmyleran | A methanesulfonate ester that is hexane-2,5-diol in which the hydrogens of the hydroxy groups are replaced by methanesulfonyl groups. | dimethylmyleran |
| ecteinascidin 743 | A tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer. | trabectedin |
| estramustine | A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid. | estramustine |
| etanidazole | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells. | etanidazole |
| ethyl methanesulfonate | A methanesulfonate ester resulting from the formal condensation of methanesulfonic acid with ethanol. | ethyl methanesulfonate |
| ethylenimine quinone | A member of the class of 1,4-benzoquinones that is p-benzoquinone in which the hydrogens at positions 2 and 5 are replaced by aziridin-1-yl groups. | 2,5-bis(aziridin-1-yl)-1,4-benzoquinone |
| ethylnitrosourea | A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups. | N-ethyl-N-nitrosourea |
| hycanthone methanesulfonate | A methanesulfonate salt resulting from the reaction of equimolar amounts of hycanthone and methanesulfonic acid. It was formerly used as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel. | hycanthone mesylate |
| ifosfamide | The simplest member of the class of ifosfamides that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by 2-chloroethyl groups on both the nitrogen atoms respectively. It is a nitrogen mustard alkylating agent used in the treatment of advanced breast cancer. | ifosfamide |
| iodoacetic acid | A haloacetic acid that is acetic acid in which one of the hydrogens of the methyl group is replaced by an iodine atom. | iodoacetic acid |
| lomustine | An N-nitrosourea that is urea in which one of the nitrogens is substituted by a 2-chloroethyl group and by a nitroso group, while the other nitrogen is substituted by a cyclohexyl group. An alkylating antineoplastic agent, it is used in the treatment of brain tumours, lung cancer, malignant melanoma and other solid tumours. | lomustine |
| mechlorethamine | | mechlorethamine |
| melphalan | A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring. | melphalan |
| methyl methanesulfonate | A methanesulfonate ester resulting from the formal condensation of methanesulfonic acid with methanol. | methyl methanesulfonate |
| methylnitronitrosoguanidine | An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position | N-methyl-N'-nitro-N-nitrosoguanidine |
| methylnitrosourea | A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups. | N-methyl-N-nitrosourea |
| mitomycin | | mitomycin C |
| mitomycin a | A member of the family of mitomycins that exhibits antibiotic and antitumour properties as well as a high level of toxicity. | mitomycin A |
| mustard gas | An ethyl sulfide that is diethyl sulfide in which a hydrogen from each of the terminal methyl groups is replaced by a chlorine. It is a powerful vesicant regulated under the Chemical Weapons Convention. | bis(2-chloroethyl) sulfide |
| nimustine | An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-amino-2-methylpyrimidin-5-ylmethyl] group. An antineoplastic agent especially effective against malignant brain tumors. | nimustine |
| nsc 224070 | A member of the class of 1,4-benzoquinones that is 1,4-benzoquinone in which the hydrogens at positions 2 and 5 have been replaced by aziridin-1-yl groups while the hydrogens at positions 3 and 6 have been replaced by (2-hydroxyethyl)amino groups. | 2,5-bis(2-hydroxyethylamino)-3,6-diaziridinylbenzoquinone |
| perfosfamide | A phosphorodiamide that is the active metabolite of the nitrogen mustard cyclophosphamide. It has potent antineoplastic and immunosuppressive properties. | 4-hydroperoxycyclophosphamide |
| pipobroman | An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug. | pipobroman |
| s-chloromethylglutathione | An S-substituted glutathione that is glutathione in which the mercapto hydrogen has been replaced by a chloromethyl group. | S-(chloromethyl)glutathione |
| semustine | An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group. | semustine |
| temozolomide | An imidazotetrazine that is 3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine which is substituted at positions 3, 4, and 8 by methyl, oxo, and carboxamide groups, respectively. A prodrug for MTIC (5-(3-methyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide, formed by spontaneous hydrolysis of temozolomide in the body), it is used as an oral alkylating agent for the treatment of newly diagnosed malignant glioblastoma multiforme (concomitantly with radiotherapy) and malignant melanoma. | temozolomide |
| tilimycin | A pyrrolobenzodiazepine that is (11aS)-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine which is substituted by an oxo group at position 5 and by hydroxy groups at positions 9 and 11. It is an enterotoxic natural product synthesized via a non-ribosomal peptide synthase in Klebsiella oxytoca. | tilimycin |
| tosylphenylalanyl chloromethyl ketone | The N-tosyl derivative of L-phenylalanyl chloromethyl ketone. | N-tosyl-L-phenylalanyl chloromethyl ketone |
| triaziquone | A member of the class of 1,4-benzoquinones that is 1,4-benzoquinone in which three of the ring hydrogens are replaced by aziridin-1-yl groups. | triaziquone |
| triethylenemelamine | | tretamine |
| trimethyl phosphite | An organophosphorus compound that is phosphane in which the three hydrogens are replaced by methoxy groups. It is an alkylating agent used primarily in the synthesis of organophosphate compounds. | trimethyl phosphite |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 25.8487 | 1 | 3 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 34.3521 | 1 | 3 |
| 67.9K protein | Vaccinia virus | Potency | 6.5967 | 2 | 3 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 18.2824 | 2 | 3 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 26.7737 | 2 | 7 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 13.6311 | 2 | 15 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 17.3582 | 1 | 2 |
| Amyloid-beta precursor protein | Homo sapiens (human) | Potency | 16.3601 | 1 | 1 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 17.4069 | 1 | 3 |
| AR protein | Homo sapiens (human) | Potency | 21.1841 | 12 | 42 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 24.5239 | 2 | 12 |
| arylsulfatase A | Homo sapiens (human) | Potency | 0.1324 | 1 | 2 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 19.9922 | 3 | 4 |
| Ataxin-2 | Homo sapiens (human) | Potency | 34.1398 | 2 | 6 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 13.3340 | 3 | 4 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 42.2963 | 2 | 8 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 11.9955 | 1 | 1 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 5.8479 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 17.3040 | 3 | 10 |
| BRCA1 | Homo sapiens (human) | Potency | 5.0119 | 1 | 1 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 56.2341 | 1 | 1 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 33.8480 | 1 | 5 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 33.8480 | 1 | 5 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 23.3970 | 3 | 32 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 13.6982 | 2 | 3 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 21.9640 | 1 | 3 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 8.1349 | 1 | 1 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 8.7649 | 1 | 2 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 10.1134 | 3 | 7 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 31.8326 | 1 | 2 |
| Chain A, PAPAIN | Carica papaya (papaya) | Potency | 15.8489 | 1 | 1 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 23.8092 | 2 | 3 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| chaperonin GroEL | Methanococcus maripaludis S2 | Potency | 100.0000 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 52.5085 | 2 | 4 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 7.5060 | 1 | 2 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 29.1086 | 1 | 3 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 13.9604 | 1 | 6 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 1.8341 | 2 | 7 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 13.7491 | 2 | 11 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 23.0060 | 1 | 9 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 20.7491 | 1 | 1 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 13.8993 | 1 | 3 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 68.3247 | 1 | 3 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 15.0524 | 1 | 2 |
| endonuclease IV | Escherichia coli | Potency | 8.5398 | 1 | 2 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 19.5043 | 12 | 71 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 22.4425 | 3 | 6 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 30.0005 | 7 | 37 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 18.7677 | 1 | 15 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 14.5366 | 4 | 30 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 30.6904 | 4 | 7 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 8.4368 | 1 | 1 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 23.0694 | 1 | 7 |
| G | Vesicular stomatitis virus | Potency | 29.1086 | 1 | 3 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| GALC protein | Homo sapiens (human) | Potency | 0.7079 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 1.6127 | 1 | 4 |
| geminin | Homo sapiens (human) | Potency | 10.3370 | 3 | 19 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 30.0425 | 2 | 16 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 7.8117 | 1 | 2 |
| GLS protein | Homo sapiens (human) | Potency | 27.3979 | 1 | 3 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 22.4075 | 4 | 11 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 13.5290 | 1 | 3 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 47.9904 | 1 | 2 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 57.2657 | 2 | 2 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 19.9526 | 1 | 3 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 5.5462 | 1 | 3 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 44.1226 | 2 | 14 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 29.1086 | 1 | 3 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 1 | 2 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 20.3944 | 1 | 2 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 18.0087 | 3 | 9 |
| IDH1 | Homo sapiens (human) | Potency | 13.2780 | 1 | 2 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 125.8920 | 1 | 1 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 29.1086 | 1 | 6 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 1 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 6.3096 | 1 | 1 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 6.3096 | 1 | 1 |
| Interferon beta | Homo sapiens (human) | Potency | 24.3372 | 3 | 13 |
| interleukin 8 | Homo sapiens (human) | Potency | 63.5896 | 1 | 4 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 8.6593 | 2 | 12 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 17.5384 | 1 | 5 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 36.0642 | 3 | 5 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 18.7870 | 2 | 8 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 10.0556 | 1 | 2 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 30.3834 | 2 | 4 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 64.0919 | 1 | 2 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 16.2710 | 1 | 2 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 4.0382 | 2 | 6 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 11.3974 | 1 | 2 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 46.5626 | 4 | 25 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 11.0095 | 1 | 2 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 27.2995 | 1 | 2 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 66.0844 | 1 | 4 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 23.5433 | 2 | 4 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 14.1684 | 1 | 4 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 16.3445 | 3 | 17 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| Parkin | Homo sapiens (human) | Potency | 20.5962 | 1 | 1 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 12.1140 | 2 | 4 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 58.4455 | 1 | 4 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 26.8321 | 5 | 16 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 34.6303 | 3 | 7 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 5.6234 | 1 | 1 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 4.9788 | 1 | 5 |
| polyprotein | Zika virus | Potency | 23.0694 | 1 | 7 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 23.0499 | 1 | 5 |
| PPM1D protein | Homo sapiens (human) | Potency | 21.7515 | 1 | 6 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 47.3277 | 3 | 10 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 35.4813 | 1 | 1 |
| progesterone receptor | Homo sapiens (human) | Potency | 16.6068 | 2 | 5 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 22.2324 | 2 | 22 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 73.0780 | 1 | 1 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 12.6511 | 1 | 2 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 43.0062 | 3 | 30 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 1,131.7935 | 3 | 18 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 19.7511 | 4 | 4 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 11.9173 | 1 | 1 |
| Smad3 | Homo sapiens (human) | Potency | 17.5203 | 1 | 3 |
| snurportin-1 | Homo sapiens (human) | Potency | 125.8920 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 19.2703 | 2 | 5 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 15.6057 | 1 | 6 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 23.4221 | 1 | 3 |
| TDP1 protein | Homo sapiens (human) | Potency | 9.0749 | 2 | 34 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 25.1548 | 1 | 3 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 38.1053 | 3 | 13 |
| Thrombopoietin | Homo sapiens (human) | Potency | 10.0000 | 2 | 4 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 20.0554 | 3 | 23 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 17.1263 | 3 | 3 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 29.7412 | 4 | 18 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 13.8993 | 1 | 3 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 4.9788 | 1 | 5 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 4.9788 | 1 | 5 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 49.3412 | 3 | 5 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 35.4736 | 2 | 9 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 13.7450 | 3 | 8 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 22.3147 | 5 | 9 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 13.5290 | 1 | 3 |
| WRN | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |